Related Experiment Video
Updated: Aug 4, 2025
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
83.7K
Sparsentan: First Approval
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
Drugs
|April 6, 2023
Summary
Sparsentan, a dual endothelin angiotensin receptor antagonist, is now approved in the USA for IgA nephropathy. This oral medication helps reduce proteinuria in adults at risk of rapid disease progression.
Area of Science:
- Nephrology
- Pharmacology
- Drug Development
Background:
- Immunoglobulin A (IgA) nephropathy is a progressive kidney disease.
- Focal segmental glomerulosclerosis (FSGS) is another serious kidney condition.
- Existing treatments for IgA nephropathy and FSGS have limitations.
Purpose of the Study:
- To summarize the development milestones of sparsentan.
- To highlight the path to its first regulatory approval for IgA nephropathy.
Main Methods:
- Review of clinical development data for sparsentan.
- Analysis of regulatory submission and approval process.
Main Results:
- Sparsentan, an oral dual endothelin angiotensin receptor antagonist, targets key pathways in kidney disease.
- Accelerated approval in the USA was granted in February 2023.
- Sparsentan is indicated for reducing proteinuria in primary IgA nephropathy patients at risk of rapid progression.
Conclusions:
- Sparsentan represents a significant advancement in IgA nephropathy treatment.
- The drug's development highlights successful targeting of dual receptor antagonism.
- This approval marks a key milestone for Travere Therapeutics and patients.
Related Concept Videos
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
207
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
207
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
232
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
232
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
3.0K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
3.0K
01:16Vascular Spasm
1.6K
The vascular phase, also known as vasospasm, is the initial stage of hemostasis, crucial for preventing excessive bleeding when a blood vessel is injured. After a vessel is cut, nerves in the damaged area trigger pain and other sensory impulses. Simultaneously, the smooth muscles in the vessel wall contract, resulting in a vascular spasm. This contraction reduces the vessel's diameter at the injury site, slowing or stopping blood loss through the vessel wall. Vascular spasms typically last...
1.6K
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
204
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
204
01:25Antihypertensive Drugs: Direct Renin Inhibitors
721
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
721